key: cord-1041589-nx45qvji
authors: Antonini, Angelo
title: Health care for chronic neurological patients after COVID-19
date: 2020-05-25
journal: Lancet Neurol
DOI: 10.1016/s1474-4422(20)30157-5
sha: 47b7509de63b1202ee32129a853b74f3d9a0bb74
doc_id: 1041589
cord_uid: nx45qvji

nan

The ongoing spread of the coronavirus disease 2019 (COVID-19) pandemic is providing an opportunity to reassess and reconsider priorities in health-care sys tems. 1 In the past two decades, high-income countries have developed the perception that we need to partly shift resources to chronic conditions and limit the number of hospital beds to admit only medical emergencies. This notion was based on the need to contain health-care spending and to care for an increasingly large ageing population, with chronic conditions becoming more common, particularly in neurology. The idea of making health care more effi cient has resulted in a management shift toward short hospitalisation, early discharge, and substantial cuts to expensive intensive care units. Many neurology clinics have substantially reduced their number of hospital beds and neurologists often prioritise consultation in busy outpatient clinics. In some countries, including the UK, it has been cheaper for national health services to hire specialised nurses rather than train more physicians.

The COVID-19 pandemic-because of which hundreds of indi viduals are presenting to hospital within a short timeframe with respiratory distress and diffuse coagulopathy-is likely to put this practice to an end for at least a few years. 2 In regions such as Lombardy (Italy), London (UK), and New York City (USA) that have ultra-specialised units but low numbers of primary care phys i cians, acute and intensive care beds per 100 000 inhab itants have reported very high mortality rates due to the inability to deal with the emergency. Cop ing with pandemics and human itar ian emergencies requires health-care systems to find a reason able balance between acute and chronic care.

In The Lancet Neurology, Bastiaan Bloem and colleagues 3 provide their view on how management of chronic neurological patients should be organised. The Personal View was written before COVID-19, but is still extremely relevant and timely in light of what has happened in these past weeks. Their starting view is that, in our health systems, care is mainly reactive and focused on tackling problems when they arise, instead of taking a proactive approach to prevention, with poor interdisciplinary collaboration and lack of timely access to services and therapies. The authors apply this concern over reactive care to Parkinson's disease and other chronic neurological disorders-but it could be also applied to the ongoing COVID-19 pandemic. Although there are some exceptions, the response implemented by politicians and medi cal experts to COVID-19 has generally been confusing and uncoordinated.

Bloem and colleagues' proposal is to develop inte grated care and to implement a home-hub-and-spoke model for Parkinson's disease care services, which could be extended to other chronic neurological diseases. 4 They pledge for increased focus on nurses based in community hospitals who act as personal care managers and deliver services remotely, possibly coordinating telemedicine activities. In this model, dedicated educational programmes should be provided to patients and caregivers. For Parkinson's disease care, this model is particularly relevant as nutrition, physical activities, and issues regarding medi cation and advanced therapies can be addressed remotely. 5 Indeed, during the current pandemic many institutions have switched to remote consultations to minimise the risk of infections to patients. 6 There are challenges to this view. In many countries this approach can only be considered if family doctors are integrated into the system and trained to offer firstlevel consultation, possibly interacting with nurse case managers at tertiary centres. Replicability of this healthcare model is also a concern considering the important differences in medical services that exist within Europe and globally. The example of the network based healthcare model in the Netherlands, ParkinsonNet, would need substantial adaptations, particularly in countries with national health services and only marginal availability of private insurance in the population (such as Italy and the UK). 7 In the USA, a large proportion of the population does not have medical coverage so the reported successful case study of Kaiser Permanente insurance in California might offer only a partial pers pective on how well patients with Parkinson's disease on low incomes are managed in the country. 8 We need to consider that in most European countries there is a shortage of doctors and nurses because health-care jobs have lost attractiveness. These roles are underpaid, stressful, and increasingly focused on administrative tasks rather than medical issues in hospitals.

In conclusion, the Personal View from Bloem and colleagues provides several important considerations that will require a thorough discussion after this acute phase. The definition of multidisciplinary teams to plan care for patients with Parkinson's diseases (and other chronic conditions) seems a very reasonable approach, although currently restricted to specific health systems, such as those in middle-income or high-income countries or national insurance-based health-care systems. The develop ment of telemedicine offers an incredible oppor tunity for remote monitoring and implementation of technology-based objective measures. 9 However, the accept ability to patients, caregivers, and clinicians of digital health platforms needs to be further assessed, possibly with dedicated trials focused on improvement in quality of life and therapeutic management. 10 

Medicine: before COVID-19, and after

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care

Moving Parkinson care to the home

Management of advanced therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience

Virtual health care in the era of COVID-19

The ParkinsonNet concept: development, implementation and initial experience

Introduction of network-based healthcare at Kaiser Permanente

Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease

AA reports grants and personal fees from Abbvie, Bial, Theravance, Biogen, Zambon, and Neuroderm, and grants from Horizon 2020, Miur Italy, Chiesi Pharmaceuticals, and Lundbeck, outside the submitted work.

Department of Neuroscience, University of Padua, Padua 35138, Italy